Scott Dahlbeck
Oprichter bij KIROMIC BIOPHARMA, INC.
Vermogen: 182 186 $ op 31-05-2024
Profiel
Scott Dahlbeck is the founder and currently holds the position of Chief of Staff at Kiromic Biopharma, Inc., a company he founded in 2006.
He is also the founder and currently holds the position of President & Chief Medical Officer at Kiromic, Inc., a company he founded in 2013.
Dr. Dahlbeck has a doctorate degree from the University of Nebraska Medical Center and The University of Texas Health Science Center at Houston.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
KIROMIC BIOPHARMA, INC.
3.69% | 15-05-2024 | 56 933 ( 3.69% ) | 182 186 $ | 31-05-2024 |
Actieve functies van Scott Dahlbeck
| Bedrijven | Functie | Begin |
|---|---|---|
| KIROMIC BIOPHARMA, INC. | Oprichter | 06-08-2006 |
Kiromic, Inc.
 Kiromic, Inc. Medical/Nursing ServicesHealth Services Kiromic, Inc. is a biotech company that has discovered a breakthrough technology called the Diamond Artificial Intelligence platform. It serves as the foundation for Kiromic’s new drug discoveries through novel target identification. The company was founded by Maurizio Chiriva-Internati and Scott Dahlbeck in 2013 and is headquartered in Houston, TX. | Oprichter | 01-01-2013 |
Opleiding van Scott Dahlbeck
| The University of Texas Health Science Center at Houston | Doctorate Degree |
| University of Nebraska Medical Center | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| KIROMIC BIOPHARMA, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Kiromic, Inc.
Kiromic, Inc. Medical/Nursing ServicesHealth Services Kiromic, Inc. is a biotech company that has discovered a breakthrough technology called the Diamond Artificial Intelligence platform. It serves as the foundation for Kiromic’s new drug discoveries through novel target identification. The company was founded by Maurizio Chiriva-Internati and Scott Dahlbeck in 2013 and is headquartered in Houston, TX. | Health Services |
